Clinical Trial Update: Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM [Phase 3]

View source ↗

Summary

Phase 3 trial results report on switching virologically suppressed HIV-1-infected patients from Lamivudine 150 mg BID plus Raltegravir 400 mg BID to Lamivudine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Lamivudine (lamivudine)
• Raltegravir (raltegravir)

Snippet

Sponsor: Judit Pich | Conditions: HIV Infections, HIV-1-infection | Phase 3 | Status: COMPLETED | Results posted: 2025-07-18